Angiogenesis is a key step in the progression of neoplasia from benign lesions to life-threatening disease. The central theme of this project is that the integration of knowledge from the molecular, cellular and tissue morphological levels will lead to a detailed understanding of the spatial and temporal regulation of angiogenesis in neonatal, normal adult and tumor settings. Subproject 1 will characterize blood vessels in normal or neoplastic tissue that form in the presence of various cytokines and inhibitors either alone or in combination. This project will also compare the gene expression of endothelium from neonatal, adult and VEGF-A overexpressing tissue. Subproject 2 seeks to characterize VEGF-A-mediated signaling pathways downstream of KDR/Flk-1 and Flt-1 and evaluate the role of these pathways in normal and tumor-induced angiogenesis. Subproject 3 will define the role of PlGF for vascularization of normal skin as well as during inflammation, carcinogenesis, experimental tumor growth, metastasis and angiogenesis. Subproject 4 seeks to characterize the multiprotein complex that functions as a receptor for thrombospondin-1 (TSP-1) on endothelial cells and determine the signaling pathways that mediate TSP-1-induced apoptosis. Core A (Administrative Support) will oversee and coordinate the scientific, fiscal and regulatory operations of the program. Core B (Morphology Support) will provide expertise in electron microscopy, in situ hybridization and confocal microscopy to the program. Core C (Cell Biology Support) will prepare and supply various types of well-characterized and standardized endothelial cells. Core D (Genomics Support) will perform the gene profiling studies and will provide bioinformatics support for data analysis and mining. Taken together, the scientific interactions, collaborations and exchange of reagents and expertise afforded by this Program Project will lead to a comprehensive understanding of the molecular, cellular and morphological basis of angiogenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA092644-04
Application #
6919228
Study Section
Subcommittee G - Education (NCI)
Program Officer
Sussman, Daniel J
Project Start
2002-06-13
Project End
2007-05-31
Budget Start
2005-06-01
Budget End
2006-05-31
Support Year
4
Fiscal Year
2005
Total Cost
$1,684,617
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Sitohy, Basel; Chang, Sunghee; Sciuto, Tracey E et al. (2017) Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels. Am J Pathol 187:2337-2347
Gross, Kayla; Wronski, Ania; Skibinski, Adam et al. (2016) Cell Fate Decisions During Breast Cancer Development. J Dev Biol 4:4
Sedic, Maja; Kuperwasser, Charlotte (2016) BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer. Cell Cycle 15:621-7
Sedic, Maja; Skibinski, Adam; Brown, Nelson et al. (2015) Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat Commun 6:7505
Mazumdar, Sohini; Arendt, Lisa M; Phillips, Sarah et al. (2015) CoREST1 promotes tumor formation and tumor stroma interactions in a mouse model of breast cancer. PLoS One 10:e0121281
Dvorak, Harold F (2015) Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy. Cancer J 21:237-43
Sciuto, Tracey E; Merley, Anne; Lin, Chi-Iou et al. (2015) Intracellular distribution of TM4SF1 and internalization of TM4SF1-antibody complex in vascular endothelial cells. Biochem Biophys Res Commun 465:338-43
Kaunisto, Aura; Henry, Whitney S; Montaser-Kouhsari, Laleh et al. (2015) NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer. Mol Oncol 9:1140-54
Dvorak, Harold F (2015) Tumors: wounds that do not heal-redux. Cancer Immunol Res 3:1-11
Lin, Chi-Iou; Merley, Anne; Sciuto, Tracey E et al. (2014) TM4SF1: a new vascular therapeutic target in cancer. Angiogenesis 17:897-907

Showing the most recent 10 out of 117 publications